A Phase 3 interventional study of Active laser photocoagulation and Sham injections in Visual Impairment Due to Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Terminated at 36 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 29th largest by enrollment, is one of 5 that started in 2010, is one of 25 in phase 3, and was the 22nd registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
39 studies in Macular Edema by Novartis: none open now, none under way, none of them phase 3. Of 37 finished, 25 (68%) have results posted.
Among the 39 studies in Macular Edema by Novartis, this one is the 21st largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2010, is one of 22 in phase 3, and was the 5th registered.
Novartis’s Macular Edema studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Novartis’s 39 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema. A subgroup of patients with Proliferative Diabetic Retinopathy were included to evaluate the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria may apply
Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment. Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Procedure: Active laser photocoagulation · Drug: Ranibizumab 0.5 mg
Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment. Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Procedure: Active laser photocoagulation · Drug: Sham injections
Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
Change in Best-Corrected Visual Acuity (BCVA) From Baseline to Month 12
Mean change in Best-Corrected Visual Acuity (BCVA) letters at 12 months compared to baseline was measured using Visual acuity (VA). VA accounts for the number of letters a participant can see using Early Treatment Diabetic Retinopathy Study (EDTRS)-like visual acuity testing charts, from a sitting position at a testing distance of 4 meters. BCVA means that the participant's refraction is already taken into account when VA is determined. A higher BCVA number at 12 months in reference to baseline indicates improved BCVA.
Time frame: 12 months
Participants did not complete study due to early termination. Study was terminated because of drug approval.
| Milestone | Active Laser Photocoagulation and Ranibizumab | Active Laser Photocoagulation and Sham Injection |
|---|---|---|
| Started | 85 | 43 |
| Completed | 0 | 0 |
| Not completed | 85 | 43 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Abnormal laboratory value | 1 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 3 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Administrative problems | 1 | 1 |
| Withdrew: Study termination | 78 | 32 |
Mean change in Best-Corrected Visual Acuity (BCVA) letters at 12 months compared to baseline was measured using Visual acuity (VA). VA accounts for the number of letters a participant can see using Early Treatment Diabetic Retinopathy Study (EDTRS)-like visual acuity testing charts, from a sitting position at a testing distance of 4 meters. BCVA means that the participant's refraction is already taken into account when VA is determined. A higher BCVA number at 12 months in reference to baseline indicates improved BCVA.
| Letters | Active Laser Photocoagulation and Ranibizumab | Active Laser Photocoagulation and Sham Injection |
|---|---|---|
| Change in Best-Corrected Visual Acuity (BCVA) From Baseline to Month 12 | 6.5 ± 8.6 | 1.4 ± 7.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Laser Photocoagulation and Ranibizumab | — | 14/85 (16.5%) | 32/85 (37.6%) |
| Active Laser Photocoagulation and Sham Injection | — | 5/43 (11.6%) | 10/43 (23.3%) |
| Event | Active Laser Photocoagulation and Ranibizumab | Active Laser Photocoagulation and Sham Injection |
|---|---|---|
| RETINAL DETACHMENT (Fellow eye)Eye disorders | 0/85 | 2/43 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 2/85 | 0/43 |
| CORONARY ARTERY DISEASECardiac disorders | 0/85 | 1/43 |
| CORONARY ARTERY STENOSISCardiac disorders | 0/85 | 1/43 |
| VITREOUS HAEMORRHAGE (Fellow eye)Eye disorders | 0/85 | 1/43 |
| CONCOMITANT DISEASE PROGRESSIONGeneral disorders | 0/85 | 1/43 |
| TYPE 1 DIABETES MELLITUSMetabolism and nutrition disorders | 0/85 | 1/43 |
| CHONDROPATHYMusculoskeletal and connective tissue disorders | 0/85 | 1/43 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/85 | 1/43 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 1/85 | 0/43 |
| Event | Active Laser Photocoagulation and Ranibizumab | Active Laser Photocoagulation and Sham Injection |
|---|---|---|
| EYE PAIN (Study eye)Eye disorders | 13/85 | 4/43 |
| NASOPHARYNGITISInfections and infestations | 13/85 | 6/43 |
| HYPERTENSIONVascular disorders | 4/85 | 4/43 |
| EYE IRRITATION (Study eye)Eye disorders | 5/85 | 0/43 |
| LACRIMATION INCREASED (Study eye)Eye disorders | 5/85 | 1/43 |
| HEADACHENervous system disorders | 5/85 | 1/43 |
| Age Continuous(years) | Active Laser Photocoagulation and Ranibizumab | Active Laser Photocoagulation and Sham Injection | Total |
|---|---|---|---|
| >=18 years | 63.5 ± 9.3 | 63.5 ± 10.5 | 63.5 ± 9.7 |
| Sex: Female, Male(Participants) | Active Laser Photocoagulation and Ranibizumab | Active Laser Photocoagulation and Sham Injection | Total |
|---|---|---|---|
| Female | 32 | 16 | 48 |
| Male | 53 | 27 | 80 |
The record gives a start of Jun 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab